ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from              to

---

---

---

(1)	Other comprehensive income (loss) consisted solely of unrealized gains or losses on available for sale securities arising during the periods presented. There were no reclassification adjustments to net income resulting from realized gains or losses on the sale of securities and there was no income tax expense related to other comprehensive income during those periods.

---

---

---

---

---

---

---

---

---

---

---

•	When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals of similar assets as observable inputs for pricing, which is a Level 2 input.

•	2019 Notes are valued using a third-party pricing model that is based in part on average trading prices, which is a Level 2 input. The 2019 Notes are not marked-to-market and are shown at their initial fair value less the unamortized discount; the portion of the value allocated to the conversion option is included in Stockholders’ equity in the accompanying Consolidated Balance Sheets.

•	We have estimated the fair value of our other debt instruments, where possible, using the net present value of the payments discounted at an interest rate that is consistent with money-market rates that would have been earned on our non-interest-bearing compensating balances, which is a Level 2 input.

---

---

---

---

---

---

---

---

---

(1)	Includes amortization of upfront payments.

(2)	Includes milestone payments.

---

•

Clinical Trial Costs — Clinical trial expenses, which include services performed by third-party contract research organizations and other vendors, increased by $15.3 million, or 105%, and $16.6 million, or 57%, respectively. The increase in clinical trial costs was primarily related to clinical trial activities for COMET-1, our phase 3 pivotal trial with the primary endpoint of overall survival in metastatic CRPC, as well as costs incurred in connection with the start-up for our phase 3 trials for metastatic RCC and metastatic HCC.

•	Consulting — Consulting expenses increased $1.1 million, or 93%, and $1.6 million, or 70%, respectively, primarily as a result of increased outsourcing of development and clinical trial activities.

•	Stock-Based Compensation — Stock-Based Compensation increased $0.5 million, or 45%, and $0.6 million, or 28%, respectively, primarily as a result of an increase in the number and valuation of new grants, as well as an increase in the participation and valuation of ESPP.

•	General Corporate Costs — There was a decrease of $0.5 million, or 9%, and $1.2 million, or 11%, respectively, in the allocation of general corporate costs (such as facility costs, property taxes and insurance) to research and development, primarily due to the decrease in drug discovery personnel resulting from the Restructurings.

---

•	Personnel — Personnel expense decreased by $0.6 million, or 4%, for the six months ended June 30, 2013, primarily due to the reduction in headcount related to the Restructurings.

•	Depreciation and Amortization — Depreciation and amortization expense decreased by $0.4 million, or 67% and $0.8 million or 58%, respectively, primarily as a result of the impairment and disposition of assets related to the Restructurings and the impact of additional assets becoming fully depreciated during 2012.

---

---

---

•	the progress and scope of the development and commercialization activities with respect to COMETRIQ (cabozantinib);

•	repayment of the 2019 Notes;

•	repayment of the Deerfield Notes;

•	repayment of our loan from Silicon Valley Bank;

•	the commercial success of COMETRIQ and the revenues we generate;

•	the level of payments received under existing collaboration agreements, licensing agreements and other arrangements;

•	the degree to which we conduct funded development activity on behalf of partners to whom we have out-licensed compounds or programs;

•	whether we enter into new collaboration agreements, licensing agreements or other arrangements (including, in particular, with respect to COMETRIQ) that provide additional capital;

•	our ability to control costs;

•	our ability to remain in compliance with, or amend or cause to be waived, financial covenants contained in agreements with third parties;

---

•	the amount of our cash and cash equivalents, short- and long-term investments that serve as collateral for bank lines of credit;

•	future clinical trial results;

•	our need to expand our product and clinical development efforts;

•	the cost and timing of regulatory approvals;

•	the cost of clinical and research supplies of our product candidates;

•	our obligation to share U.S. marketing and commercialization costs for cobimetinib (GDC-0973/XL518) under our collaboration with Genentech;

•	our ability to share the costs of our clinical development efforts with third parties;

•	the effect of competing technological and market developments;

•	the filing, maintenance, prosecution, defense and enforcement of patent claims and other intellectual property rights; and

•	the cost of any acquisitions of or investments in businesses, products and technologies.

---

---

•	fund our operations and clinical trials;

•	continue our research and development efforts; and

•	commercialize our product candidates, if any such candidates receive regulatory approval for commercial sale.

•	the progress and scope of the development and commercialization activities with respect to COMETRIQ® (cabozantinib);

•	repayment of our $287.5 million aggregate principal amount of the 2019 Notes that mature on August 15, 2019, unless earlier converted, redeemed or repurchased;

•

repayment of the $114.0 million initial principal amount of the Deerfield Notes, for which we will be required to make mandatory prepayments on an annual basis in 2014 and 2015 equal to 15% of specified payments from our collaborative arrangements received during the prior fiscal year, subject to a maximum annual prepayment amount of $27.5 million and, for the payment due in January 2014, a required minimum prepayment amount of $10.0 million, unless we are able to repay them with our common stock, which we are only able to do under specified conditions;

•	repayment of our term loan and line of credit from Silicon Valley Bank, which had an outstanding balance at June 30, 2013, of $83.7 million;

•	the commercial success of COMETRIQ and the revenues we generate;

•	the level of payments received under existing collaboration agreements, licensing agreements and other arrangements;

•	the degree to which we conduct funded development activity on behalf of partners to whom we have out-licensed compounds or programs;

---

•	whether we enter into new collaboration agreements, licensing agreements or other arrangements (including, in particular, with respect to COMETRIQ) that provide additional capital;

•	our ability to control costs;

•	our ability to remain in compliance with, or amend or cause to be waived, financial covenants contained in agreements with third parties;

•	the amount of our cash and cash equivalents, short- and long-term investments that serve as collateral for bank lines of credit;

•	future clinical trial results;

•	our need to expand our product and clinical development efforts;

•	the cost and timing of regulatory approvals;

•	the cost of clinical and research supplies of our product candidates;

•	our obligation to share U.S. marketing and commercialization costs for cobimetinib (GDC-0973/XL518) under our collaboration with Genentech;

•	our ability to share the costs of our clinical development efforts with third parties;

•	the effect of competing technological and market developments;

•	the filing, maintenance, prosecution, defense and enforcement of patent claims and other intellectual property rights; and

•	the cost of any acquisitions of or investments in businesses, products and technologies.

---

•	making it more difficult for us to meet our payment and other obligations under the 2019 Notes, the Deerfield Notes, our loan and security agreement with Silicon Valley Bank or our other indebtedness;

•	resulting in an event of default if we fail to comply with the financial and other restrictive covenants contained in our debt agreements, which event of default could result in all of our debt becoming immediately due and payable;

•	increasing our vulnerability to adverse economic and industry conditions;

•	subjecting us to the risk of increased sensitivity to interest rate increases on our indebtedness with variable interest rates, including borrowings under our loan and security agreement with Silicon Valley Bank;

•	limiting our ability to obtain additional financing;

•	requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, thereby reducing the amount of our cash flow available for other purposes, including working capital, capital expenditures, acquisitions and other general corporate purposes;

•	limiting our flexibility in planning for, or reacting to, changes in our business;

•	preventing us from raising funds necessary to purchase the 2019 Notes in the event we are required to do so following a “Fundamental Change” as specified in the indenture governing the 2019 Notes, or to settle conversions of the 2019 Notes in cash;

•	dilution experienced by our existing stockholders as a result of the conversion of the 2019 Notes or the Deerfield Notes into shares of common stock; and

•	placing us at a possible competitive disadvantage with less leveraged competitors and competitors that may have better access to capital resources.

---

---

•	the effectiveness, or perceived effectiveness, of COMETRIQ in comparison to competing products;

•	the existence of any significant side effects of COMETRIQ, as well as their severity in comparison to those of any competing products;

•	potential advantages or disadvantages in relation to alternative treatments;

•	the timing of market entry relative to competitive treatments;

•	indications for which COMETRIQ is approved;

•	the ability to offer COMETRIQ for sale at competitive prices;

•	relative convenience and ease of administration;

•	the strength of sales, marketing and distribution support; and

•	sufficient third-party coverage or reimbursement.

•	the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology and Clinical Health Act and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;

•

the federal healthcare programs’ Anti-Kickback Law, which constrains our marketing practices, educational programs, pricing policies, and relationships with healthcare providers or other entities, by prohibiting, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or

---

•	federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;

•	federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;

•

state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating efforts;

•	the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals);

•	federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;

•

state and federal government price reporting laws that require us to calculate and report complex pricing metrics to government programs, where such reported priced may be used in the calculation of reimbursement and/or discounts on our marketed drugs (participation in these programs and compliance with the applicable requirements may subject us to potentially significant discounts on our products, increased infrastructure costs, and potentially limit our ability to offer certain marketplace discounts); and

•

state and federal marketing expenditure tracking and reporting laws, which generally require certain types of expenditures in the United States to be tracked and reported (compliance with such requirements may require investment in infrastructure to ensure that tracking is performed properly, and some of these laws result in the public disclosure of various types of payments and relationships, which could potentially have a negative effect on our business and/or increase enforcement scrutiny of our activities).

---

---

•	cabozantinib may not prove to be efficacious or may cause, or potentially cause, harmful side effects;

•	negative or inconclusive clinical trial results may require us to conduct further testing or to abandon projects that we had expected to be promising;

---

•	our competitors may discover or commercialize other compounds or therapies that show significantly improved safety or efficacy compared to cabozantinib;

•	patient registration or enrollment in our clinical testing may be lower than we anticipate, resulting in the delay or cancellation of clinical testing; and

•	regulators or institutional review boards may withhold authorization of, or delay, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or their determination that participating patients are being exposed to unacceptable health risks.

•	the number of patients who ultimately participate in the clinical trial;

•	the duration of patient follow-up that is appropriate in view of the results or required by regulatory authorities;

•	the number of clinical sites included in the trials; and

•	the length of time required to enroll suitable patient subjects.

---

•	A concern about the ability to maintain blinding of the trial due to differences in toxicity profiles between cabozantinib and mitoxantrone.

•	A view that the assumed magnitude of pain improvement is modest and could represent a placebo effect or be attained with less toxicity by opioid therapy.

•	A view that symptomatic improvement should be supported by evidence of anti-tumor activity, an acceptable safety profile and lack of survival decrement. The FDA also expressed the view that if the effect that we believe cabozantinib will have on pain is mediated by anti-tumor activity, that anti-tumor activity should translate into an improvement in overall survival.

•

A recommendation that if we use pain response as a primary efficacy endpoint, that we conduct two adequate and well-controlled trials to demonstrate effectiveness as, according to the FDA, a conclusion based on two persuasive studies will always be more secure. The FDA advised that for a single randomized trial to support an NDA, the trial must be well designed, well conducted, internally consistent and provide statistically persuasive efficacy findings so that a second trial would be ethically or practically impossible to perform.

---

•	we may not be able to control the amount of U.S. marketing and commercialization costs for cobimetinib (GDC-0973/XL518) we are obligated to share under our collaboration with Genentech;

•	we are not able to control the amount and timing of resources that our collaborators or potential future collaborators will devote to the development or commercialization of drug candidates or to their marketing and distribution;

•	collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing;

•	disputes may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization of our drug candidates or that result in costly litigation or arbitration that diverts management’s attention and resources;

•	collaborators may experience financial difficulties;

•	collaborators may not be successful in their efforts to obtain regulatory approvals in a timely manner, or at all;

•	collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our proprietary information or expose us to potential litigation;

•	business combinations or significant changes in a collaborator’s business strategy may adversely affect a collaborator’s willingness or ability to complete its obligations under any arrangement;

•	a collaborator could independently move forward with a competing drug candidate developed either independently or in collaboration with others, including our competitors;

•	we may be precluded from entering into additional collaboration arrangements with other parties in an area or field of exclusivity;

•	future collaborators may require us to relinquish some important rights, such as marketing and distribution rights; and

•	collaborations may be terminated (as occurred with respect to cabozantinib and XL281, which were previously subject to our 2008 collaboration agreement with Bristol-Myers Squibb, and with respect to our 2009 discovery collaboration with Sanofi, which was terminated in December 2011) or allowed to expire, which would delay, and may increase the cost of development of, our drug candidates.

---

---

---

•	the progress and scope of our development and commercialization activities;

•	the commercial success of COMETRIQ and the revenues we generate;

•	recognition of upfront licensing or other fees or revenues;

•	payments of non-refundable upfront or licensing fees, or payment for cost-sharing expenses, to third parties;

•	acceptance of our technologies and platforms;

•	the success rate of our efforts leading to milestone payments and royalties;

•	the introduction of new technologies or products by our competitors;

•	the timing and willingness of collaborators to further develop or, if approved, commercialize our product out-licensed to them;

•	our ability to enter into new collaborative relationships;

•	the termination or non-renewal of existing collaborations;

---

•	the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib;

•	adjustments to expenses accrued in prior periods based on management’s estimates after the actual level of activity relating to such expenses becomes more certain;

•	the impairment of acquired goodwill and other assets;

•	the impact of the Restructurings; and

•	general and industry-specific economic conditions that may affect our collaborators’ research and development expenditures.

•	adverse results or delays in our or our collaborators’ clinical trials;

•	announcement of FDA approval or non-approval, or delays in the FDA review process, of cabozantinib or our collaborators’ product candidates or those of our competitors or actions taken by regulatory agencies with respect to our, our collaborators’ or our competitors’ clinical trials;

•	the commercial success of COMETRIQ and the revenues we generate;

•	the timing of achievement of our clinical, regulatory, partnering and other milestones, such as the commencement of clinical development, the completion of a clinical trial, the filing for regulatory approval or the establishment of collaborative arrangements for one or more of our out-licensed programs and compounds;

•	actions taken by regulatory agencies with respect to cabozantinib or our clinical trials for cabozantinib;

•	the announcement of new products by our competitors;

•	quarterly variations in our or our competitors’ results of operations;

•	developments in our relationships with our collaborators, including the termination or modification of our agreements;

•	conflicts or litigation with our collaborators;

•	litigation, including intellectual property infringement and product liability lawsuits, involving us;

•	failure to achieve operating results projected by securities analysts;

•	changes in earnings estimates or recommendations by securities analysts;

•	financing transactions;

•	developments in the biotechnology or pharmaceutical industry;

•	sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;

•	departures of key personnel or board members;

•	developments concerning current or future collaborations;

•	FDA or international regulatory actions;

•	third-party reimbursement policies;

•	disposition of any of our subsidiaries, technologies or compounds; and

•	general market, economic and political conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.

---

•	a classified Board of Directors;

•	a prohibition on actions by our stockholders by written consent;

•	the inability of our stockholders to call special meetings of stockholders;

•	the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a “poison pill” that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors;

---

•	limitations on the removal of directors; and

•	advance notice requirements for director nominations and stockholder proposals.

---

---

---

---

ARTICLE 1	DEFINITIONS    2

1.2	“Affiliate”     2

1.3	“Agreement”    2

1.4	“Alliance Managers”    2

1.6	“Artemis”    2

1.7	“Artemis Agreement”    2

1.8	“Artemis Intellectual Property”    2

1.9	“Back-up Compound”    2

1.10	“Bankruptcy Code”    2

1.12	“Biotherapeutic Product”    3

1.13	“Biotherapeutic Target”    3

1.14	“Breaching Party”    3

1.15	“Calendar Quarter”    3

1.16	“cGMP”    3

1.17	“Change of Control”    3

1.20	“Collaboration Committee”    3

1.21	“Collaboration Compound”    3

1.22	“Collaboration Targets”    3

1.23	“Collaboration Technology”    4

1.24	“Combination Product”    4

1.25	“Commercialization Liaison”    4

1.26	“Commercialization Program”    4

1.27	“Commercialization Term”    4

1.28	“Competitive Infringement”    4

1.29	“Competitive Product”    4

1.31	“Compound Patents”    4

1.32	“Confidential Information”    4

1.33	“Contract Year”    4

1.34	“Control,” “Controls,” “Controlled” or “Controlling”    4

1.35	“Co-promote” or “Co-promotion”    5

1.36	“Co-promotion Right”    5

1.37	“Cost of Goods Sold”    5

1.39	“Developability Criteria”    5

---

1.40	“Development Candidate”    5

1.41	“Development Candidate Liaison”    5

1.42	“Development Candidate Plan”    5

1.43	“Development Compound”    5

1.44	“Development Election”    5

1.45	“Development Information”    5

1.46	“Development Operating Plan” or “DOP”    5

1.47	“Development Program”    5

1.48	“Development Term”    6

1.49	“Disclosing Party”    6

1.50	“Drafting Party”    6

1.51	“Effective Date”    6

1.52	“EMEA”    6

1.53	“Employee Agreements”    6

1.54	“Encumbered Compound”    6

1.55	“Encumbered Target”    6

1.56	“Excluded Targets”    6

1.57	“Executive Officers”    6

1.58	“EXEL”    6

1.59	“EXEL Biotherapeutic Product”    6

1.61	“EXEL Know-How”    6

1.62	“EXEL Patents”    7

1.63	“EXEL Product”    7

1.64	“EXEL Technology”    7

1.65	“Existing Biotherapeutic Target”    7

1.66	“Existing Compound”    7

1.67	“Existing Targets”    7

1.68	“Existing Third Party Collaboration”    7

1.69	“Expanded Program Option”    7

1.70	“Extension Period”    7

1.71	“FDA”     7

1.72	“Field    7

1.73	“First Commercial Sale”    8

---

1.74	“First Option Period”    8

1.75	“Follow-up Compound”    8

1.76	“Future Third Party Collaboration”    8

1.77	“Gross Margin”    8

1.78	“GSK”    8

1.80	“GSK Know-How”    8

1.82	“GSK Patents”    9

1.84	“GSK Technology”    9

1.87	“Included Compound”    9

1.88	“IND”    9

1.89	“Indemnitee”    9

1.90	“Information”    9

1.91	“Invention”    10

1.92	“Loan Agreement”    10

1.93	“Licensed Product(s)”    10

1.94	“Licensed Product Diligence Plan”    10

1.95	“Limited Program Option”    10

1.96	“Losses”    10

1.97	“Major Country”    10

1.99	“Marketing Approval”    10

1.100	“Marketing Approval Application” or “MAA”    10

1.102	“Net Sales”    11

1.103	“Non-breaching Party”    12

1.104	“Non-Selected Target”    12

1.105	“North America”    12

1.106	“Oncology Collaborator”    12

1.108	“Other Field”    12

1.109	“Party” or “Parties”    12

1.110	“Patent”    12

1.111	“Patent Costs”    12

1.112	“Patent Subcommittee”    12

1.113	“Payee”    12

1.114	“Payor”    12

---

1.115	“Person”    12

1.116	“Pipeline Option Period”    12

1.117	“Pivotal Registration Study”    12

1.118	“Product”    12

1.119	“Product Acceptance Milestone”    13

1.120	“Product Report”    13

1.121	“Proposed Biotherapeutic Target”    13

1.122	“Proof of Concept Trial” or “PoC Trial”    13

1.123	“Prosecuting Party”    13

1.124	“Prosecution and Maintenance” or “Prosecute and Maintain”    13

1.125	“Receiving Party”    13

1.126	“Refused Candidate”    13

1.127	“Regulatory Authority” or “Regulatory Authorities”    13

1.128	“Report Date”    13

1.129	“Research and Development Payments”    13

1.130	“Returned Licensed Product”    13

1.131	“Review Subcommittee”    13

1.133	“Second Option Period”    14

1.134	“Stock Purchase Agreement”    14

1.135	“Subcommittee”    14

1.136	“Subject Transaction”    14

1.137	“Sublicensee”    14

1.138	“Subsequent Product Report”    14

1.139	“Subsequently Affiliated Company”    14

1.140	“Successful PoC Completion”    14

1.141	“Target Product Profile”    14

1.142	“Term”    14

1.143	“Territory”    14

1.144	“Third Party”    14

1.145	“United States” or “U.S.”    14

1.146	“Written Disclosure”    14

---

ARTICLE 2	OVERSIGHT OF THE COLLABORATION    15

2.1	In General    15

2.2	The Collaboration Committee    15

2.3	Alliance Managers    18

2.4	Liaisons    18

2.5	Biotherapeutic Targets    18

ARTICLE 3	DEVELOPMENT PROGRAM    19

3.1	Commencement; Term    19

3.2	Objectives; Diligence    20

3.3	Development Operating Plan; Development Candidate Plan(s)    24

3.4	Development Candidate Liaison    27

3.5	Program Option Election    27

3.6	Regulatory Matters    29

3.7	Exchange of Information    30

3.8	Development Program Funding    30

3.9	Future Acquired Technology    32

3.10	GSK Technology    32

3.11	Subcontracting    32

ARTICLE 4	GSK’S ELECTION RIGHTS    33

4.1	Development Election    33

4.2	Product Report    33

4.3	Development Election Options    33

4.4	The Discussion Opportunity    35

ARTICLE 5	GRANT OF RIGHTS; COMMERCIALIZATION    36

5.1	License Grants    36

5.2	Technology Transfer    37

5.3	Commercialization Program    38

5.4	Competitive Products    40

5.5	Returned Licensed Products    41

ARTICLE 6	MILESTONES AND ROYALTIES; PAYMENTS    42

6.1	Upfront Payment to EXEL    42

6.2	Milestones Payments to EXEL    42

6.3	Royalty Payments to EXEL    45

---

6.4	Royalty Payments to GSK    48

6.5	Payments    50

6.6	Audits    50

6.7	Taxes    51

6.8	Credit against Payments for Third Party License    51

6.9	Compulsory Licenses    52

ARTICLE 7	EXCLUSIVITY    52

7.1	EXEL Prohibited Activities    52

7.2	EXEL Permitted Activities    52

7.3	GSK Activities    53

7.4	Existing Third Party Collaborations    53

7.5	Excluded Compounds    54

ARTICLE 8	OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT

8.1	Ownership    54

8.2	Patent Costs    56

8.3	Enforcement Rights    57

ARTICLE 9	CONFIDENTIALITY    58

9.1	Confidentiality; Exceptions    58

9.2	Authorized Disclosure    59

9.3	Additional Confidentiality Requirements    59

9.4	Termination of Prior Agreement    60

9.5	Remedies    60

9.6	Publications    60

ARTICLE 10	REPRESENTATIONS; WARRANTIES AND COVENANTS    60

10.1	Representations and Warranties of Both Parties    60

10.2	Representations and Warranties of EXEL    61

10.3	Covenants of EXEL    63

10.4	Representation and Warranty of GSK    64

10.5	Covenants of GSK    64

10.6	Disclaimer    64

ARTICLE 11	INDEMNIFICATION; INSURANCE    64

11.1	Indemnification by GSK    64

11.2	Indemnification by EXEL    65

---

11.3	Procedure    65

11.4	Complete Indemnification    65

11.5	Insurance    65

ARTICLE 12	TERM AND TERMINATION    66

12.1	Term; Expiration    66

12.2	Termination for Cause; Other Breaches    66

12.3	GSK Unilateral Termination Rights    67

12.4	Termination for Insolvency    67

12.5	Effect of Termination upon Certain Payment Terms    67

12.6	Effect of Termination    68

ARTICLE 14	MISCELLANEOUS    79

14.1	Publicity    79

14.2	Dispute Resolution    80

14.3	Governing Law; Jurisdiction    80

14.5	Assignment    80

14.7	Performance Warranty    81

14.8	Force Majeure    81

14.9	Notices    81

14.10	Export Clause    82

14.11	Waiver    83

14.12	Severability    83

14.13	Entire Agreement    83

14.14	Independent Contractors    83

14.15	Headings    83

14.16	Use of Name    83

14.17	Books and Records    83

14.18	Further Actions    83

14.19	Parties in Interest    83

14.20	Construction of Agreement    83

14.21	Supremacy    84

14.22	Counterparts    84

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---